Answers are grounded in this paper and cite their sources.
Over the past couple of decades considerable progress has been made in the management of metastatic colorectal cancers (mCRC) leading to a significant improvement in five-year survival. Although part of this success has been rightly attributed to aggressive surgical management and advances in other adjunct treatments, our understanding of the pathogenesis of cancer and emergence of newer molecular targets for colon cancer has created a powerful impact. In this review article we will discuss various targeted therapies in the management of mCRC. Newer agents on the horizon soon to be incorporated in clinical practice will be briefly reviewed as well.
No takes yet. Share an insight, caveat, or question.
Sachin Gopalkrishna Pai (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: